Hypertension is an important public health challenge in the United States and other countries because of its high prevalence and the concomitant increased risk of cardiovascular disease and premature death.\(^1\)\(^-\)\(^3\) Primary prevention of hypertension provides an attractive opportunity to interrupt and prevent the continuing costly cycle of managing hypertension and its complications.\(^4\) National guidelines identify lifestyle modifications as important elements in the prevention and treatment of hypertension and recommend this approach to the entire population.\(^4\)\(^-\)\(^5\) Physical activity, weight reduction, dietary sodium reduction, moderation of alcohol consumption, potassium supplementation, and consumption of a diet rich in fruits, vegetables, and low-fat dairy products, along with reductions in saturated and total fat, have been recommended as effective approaches for the prevention of hypertension.\(^4\)

**Editorial see p 538**

**Clinical Perspective on p 595**

Observational epidemiological studies have reported inconsistent findings on the relationship between dietary protein intake and blood pressure (BP).\(^6\)\(^-\)\(^8\) For example, the INTERMAP Study (International Collaborative Study of Macronutrients, Micronutrients and Blood Pressure), a cross-sectional epidemiological study of 4680 persons 40 to 59 years of age from 4 countries, found a significant inverse...
relationship between total vegetable protein intake and BP but no significant association between total animal protein and BP. There are very limited data from randomized, controlled trials to assess the effect of dietary protein on BP. In most of these trials, change in BP was not the primary outcome of interest, the sample size was small, and only a single BP measurement was obtained at the baseline and termination visits. In addition, the effects of animal protein and vegetable protein on BP have not been compared in clinical trials. We report here the results from a randomized, crossover–designed trial to test the effect of soy protein and milk protein supplementations on BP in men and women ≥22 years of age with prehypertension or stage 1 hypertension.

Methods

Study Design

The Protein and Blood Pressure (ProBP) study was a randomized, double-blinded, placebo-controlled phase III clinical trial designed to test whether a soy protein or milk protein supplementation would reduce systolic BP compared with a complex carbohydrate. The ProBP study used a crossover study design with 3 intervention phases. After a 2-week run-in period, eligible participants were allocated to receive 40 g of soy protein per day, 40 g of milk protein per day, and 40 g of complex carbohydrate (placebo) per day in a random order, each for 8 weeks. During the run-in period, study participants received 40 g of complex carbohydrate supplement. A 3-week washout period was implemented between each intervention period. Patient recruitment and the intervention occurred between September 2003 and April 2008.

Written informed consent was obtained from each participant before the initial screening visit and before randomization. The institutional review boards at the Tulane University Health Sciences Center and the University of Mississippi Medical Center approved the study protocol.

Study Participants

The study participants were men and women ≥22 years of age who had a mean systolic BP from 120 to 159 mm Hg and a diastolic BP from 80 to 95 mm Hg based on 6 readings at 2 screening visits. Persons with a systolic BP ≥160 mm Hg or a diastolic BP ≥95 mm Hg or who were taking antihypertensive medications were excluded. In addition, persons with a self-reported history of clinical cardiovascular disease, cancer, chronic kidney disease (or a serum creatinine ≥1.7 mg/dL for men and ≥1.5 mg/dL for women), hypercholesterolemia (or serum total cholesterol ≥240 mg/dL), diabetes mellitus (or serum glucose ≥126 mg/dL), body mass index ≥30 kg/m², or consumption of more than 14 drinks of alcoholic beverages per week were excluded. Persons who consumed dietary protein ≥1.63 g·kg⁻¹·d⁻¹ (85th percentile of dietary protein intake in the US general population) on the basis of two 24-hour dietary recalls were also excluded. Finally, women who were pregnant or who intended to become pregnant during the study were excluded.

The study participants were recruited by mail mailing and worksite/community-based BP screenings in New Orleans, LA, and Jackson, MS. We invited 1626 persons to the study clinics for screening visits, and 391 persons met all eligibility criteria (Figure 1). Of those ineligible, 27 individuals were taking antihypertensive medications; 61 had mean BP ≥160/95 mm Hg; 686 had mean BP ≥120/80 mm Hg; 23 had body mass index ≥40 kg/m²; 96 had clinical cardiovascular disease, chronic kidney disease, dyslipidemia, or diabetes; 38 met other exclusion criteria; and 304 declined to participate. Among those who met inclusion criteria, 352 successfully completed a 2-week run-in (intake of ≥85% supplements) and were randomized to the intervention.

Intervention

The study participants were randomly assigned to 3 sequences at a fixed 1:1:1 allocation ratio. The 3 groups received supplements in different orders: Sequence A received 40 g of soy protein for 8 weeks, then 40 g of milk protein for 8 weeks, and finally 40 g of complex carbohydrate for 8 weeks; those who were assigned to sequence B first received milk protein, then carbohydrate, and finally soy protein; and those who were assigned to sequence C first received carbohydrate, then soy protein, and finally milk protein. The randomization was stratified by clinic site, sex, and hypertension status and used a block size of 6. The randomization assignment was conducted centrally at the Data Coordinating Unit at Tulane University. After eligibility was determined, the study coordinator telephoned the Data Coordinating Unit to obtain the randomization assignment. The randomization assignment list was generated by a computer program that could only be accessed by the study data coordinator. Apart from the data coordinator, all research personnel, including study coordinators and BP technicians, and the study participants were unaware of treatment assignment.

The soy protein, milk protein, and complex carbohydrate supplements were provided for the ProBP study by Solae, LLC, St Louis, MO. The contents of sodium, potassium, and calcium in soy protein, milk protein, and complex carbohydrate were comparable (Table 1). Phosphorus was slightly higher in soy protein than milk protein and complex carbohydrate, whereas the glycemic index was higher in complex carbohydrate than in soy protein and milk protein. The average glycemic index of each supplement was calculated by summing the products of carbohydrate contents (sucrose, fructose, and maltodextrin in grams, separately), multiplying their glycemic index, and then dividing by the total carbohydrate in each supplement. In addition, glutamic acid was slightly higher in soy protein than milk protein. The soy protein, milk protein, and complex carbohydrate powders looked and tasted the same and were provided to study participants in identical packets. The study participants were instructed to take the supplements twice per day, once in the morning.
Table 1. Nutrient Composition of Soy Protein, Milk Protein, and Complex Carbohydrate Supplements, Per Day*  

<table>
<thead>
<tr>
<th></th>
<th>Soy Protein</th>
<th>Milk Protein</th>
<th>Carbohydrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy, kcal</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Protein, g</td>
<td>40</td>
<td>40</td>
<td>0.4</td>
</tr>
<tr>
<td>Carbohydrate, g</td>
<td>8</td>
<td>10</td>
<td>50</td>
</tr>
<tr>
<td>Fat, g</td>
<td>1.2</td>
<td>0.2</td>
<td>0</td>
</tr>
<tr>
<td>Saturated fat, g</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Sodium, mg</td>
<td>428</td>
<td>464</td>
<td>420</td>
</tr>
<tr>
<td>Potassium, mg</td>
<td>480</td>
<td>420</td>
<td>380</td>
</tr>
<tr>
<td>Calcium, mg</td>
<td>160</td>
<td>160</td>
<td>160</td>
</tr>
<tr>
<td>Phosphorus, mg</td>
<td>120</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Glutamic acid, g</td>
<td>8.6</td>
<td>7.8</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Isoflavone, mg</td>
<td>84</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Glycemic index†</td>
<td>47.7</td>
<td>67.2</td>
<td>98.9</td>
</tr>
</tbody>
</table>

*Nutrient composition of soy protein, milk protein, and complex carbohydrate supplements was provided by Solae, LLC, St Louis, MO.
†Glycemic index was calculated with a scale in which glucose equaled 100.

and once in the evening, in water or juice. On the basis of the participants’ two 24-hour dietary recalls during screening visits, individualized recommendations were given in order for participants’ total energy intake to remain consistent over the supplementation periods; for example, protein and carbohydrate supplement was recommended to partially replace breakfast, snack, or supper on the basis of participants’ diet habits. Participants were also instructed to maintain their usual level of physical activity, alcohol intake, and dietary sodium intake. The study participants returned unconsumed packets at their follow-up clinical visits. The study coordinator counted the number of returned packets, and we used this to assess the participants’ adherence to their assigned intervention.

Measurements

Two baseline and 2 termination visits were conducted during each intervention/control phase. At each visit, 3 BP readings were measured with a Hawksley random-zero sphygmomanometer by trained and certified observers who were masked to group assignment. BP readings were taken from the right arm with appropriately sized cuffs after the participant had been seated quietly for 5 minutes. The participant was instructed not to eat, smoke, drink alcohol, or exercise for at least 30 minutes before their BP measurements. Body weight, height, and waist circumference were measured by trained staff using a standard protocol, and body mass index was calculated in kilograms per meter squared. Two 24-hour dietary recalls were conducted at the screening visits and at the termination visits during each intervention/control phase. Computer software (Nutrition Data System for Research) was used to conduct 24-hour dietary recalls and calculate nutrient intakes.12 An overnight timed urinary sample was collected at the baseline and termination visits to measure urinary excretion of sodium, potassium, urea nitrogen, and creatinine. Side effects and compliance were assessed with a questionnaire, packet counts, and self-reported supplement calendar report.

Statistical Analysis

The ProBP study was designed to provide greater than 90% statistical power to detect a 2.0-mm Hg reduction in systolic BP at a significance level of 0.0167 (0.05/3 for the Bonferroni correction of multiple comparisons) using a 2-tailed test. The 24-hour dietary nutrient intake and urinary excretion of sodium, potassium, urea nitrogen, and creatinine were compared among 3 phases by repeated-measures ANOVA.

The primary outcome of interest was the net difference in change of systolic and diastolic BP among the 3 intervention phases. The change of BP was calculated as termination value minus baseline value within each intervention phase. Means of 6 BP readings taken during the 2 baseline visits and during the 2 termination visits were used for analysis. A mixed-effects model was used to assess the effects of protein supplementation on the change of BP, in which participants were assumed to be random effects and treatment, sequence, and period were assumed to be estimable fixed effects. PROC MIXED of SAS version 9.2 (SAS Institute Inc, Cary, NC) was used to obtain point estimates and standard errors of the treatment, sequence, and period effects and to test for differences between treatments. An autoregressive correlation matrix was used to correct within-subject correlation for repeated measurements. We examined the carryover effect by testing period×treatment interaction, and the interaction was not statistically significant. The intention-to-treat principle was used for all primary analyses. If a participant withdrew or was lost to follow-up from the study, the baseline BP was used as the termination value (change in BP equal to 0) within each phase. In a secondary analysis, we repeated the analysis only in participants who fully completed the study.

Results

The baseline characteristics of the study participants by randomization groups are displayed in Table 2. Mean systolic/diastolic BP was 126.7/82.4 mm Hg, and the proportion of participants with hypertension was 18.5%. Of 352 study participants, 284 (80.7%) had BPs measured at the end of the soy protein supplementation phase, 286 (81.3%) had BPs measured at the end of the milk protein supplementation phase, and 287 (81.5%) had BPs measured at the end of the carbohydrate supplementation phase (Figure 1). On the basis of the returned packet counts and supplement calendar report, the study participants who completed the supplementation intervention consumed more than 85% of their supplements during the corresponding intervention phase.

Table 3 presents daily dietary nutrient intake according to intervention phases from 24-hour dietary recall. On average, dietary protein intake was significantly increased in soy protein (30.5 g/d) and milk protein (32.8 g/d) supplementation phases compared with carbohydrate supplementation, whereas carbohydrate intake was significantly decreased in soy protein (30.7 g/d) and milk protein (30.6 g/d) supplementation phases. The dietary intakes of total energy, fat, saturated fat, sodium, potassium, and calcium were not significantly different among the 3 intervention/control phases.
During the intervention period, urinary excretion of urea nitrogen was significantly increased in the soy protein and milk protein supplementation phases compared with the carbohydrate supplementation phase (Table 3). Mean overnight urinary excretion of sodium, potassium, and creatinine was not significantly different among the 3 intervention phases. In addition, body weight, fasting plasma glucose, total cholesterol, low-density lipoprotein cholesterol, and triglyceride were not significantly different among the 3 intervention/control phases. High-density lipoprotein cholesterol was significantly higher in the soy protein supplementation group (Table 4).

Mean systolic BP was reduced by 1.5 mm Hg (95% confidence interval [CI] 2.4 to -0.6, \(P=0.002\)) from baseline during soy protein supplementation and by 1.8 mm Hg (95% CI -2.7 to -1.0, \(P<0.001\)) from baseline during milk protein supplementation, whereas systolic BP did not significantly change during carbohydrate supplementation (Table 5). Diastolic BP was not significantly changed during soy protein, milk protein, or carbohydrate supplementations. Compared with the carbohydrate control experience, soy protein supplementation was significantly associated with a -2.0-mm Hg (95% CI -3.2 to -0.7 mm Hg, \(P=0.002\)) net change in systolic BP, and milk protein supplementation was significantly associated with a -2.3 mm Hg (-3.7 to -1.0 mm Hg, \(P=0.0007\)) net change in systolic BP (Figure 2). There was no significant difference between the BP reductions achieved with soy or milk protein supplementation.

In a secondary analysis limited to participants who completed the entire trial, mean systolic BP was reduced by 1.6 mm Hg (95% CI -2.5 to -0.7 mm Hg, \(P=0.003\)) from baseline during soy protein supplementation and by 1.5 mm Hg (95% CI -2.4 to -0.6 mm Hg, \(P=0.009\)) from baseline during milk protein supplementation. Systolic BP did not significantly change during carbohydrate supplementation (0.4 mm Hg; 95% CI -0.6 to 1.3 mm Hg, \(P=0.85\)). Diastolic BP did not change significantly during any of the 3 interventions.

Side effects were similar among the 3 groups. Percentages of self-reported change in appetite (28.0%, 26.1%, and 22.0%; \(P=0.24\)), stomach upset or nausea (10.1%, 9.8%, and 7.7%; \(P=0.55\)), stomach pain or burning (4.6%, 3.8%, and 4.9%; \(P=0.82\)), diarrhea (4.9%, 2.8%, and 4.2%; \(P=0.42\)), constipation (14.0%, 15.0%, and 11.9%; \(P=0.54\)), red blood in the stool or blackened stools (1.4%, 2.1%, and 1.7%; \(P=0.69\)), frequent urination (11.2%, 14.3%, and 9.8%; \(P=0.23\)), excessive gas (19.2%, 16.4%, and 15.0%; \(P=0.38\)), excessive thirst (12.2%, 10.5%, and 11.2%; \(P=0.79\)), and change in sexual drive (4.9%, 2.8%, and 3.1%; \(P=0.35\)) were similar in the soy protein, milk protein, and carbohydrate supplementation phases, respectively. Participants reported more bad taste in their mouth during soy protein supplementation (16.4%, 10.5%, and 8.0%; \(P=0.005\)) and more belching during soy protein and milk protein supple-
mentation (16.5%, 15.7%, and 7.7%; \(P=0.003\)) compared with carbohydrate control.

**Discussion**

This randomized, controlled trial indicates that compared with carbohydrate intake, both soy protein and milk protein supplementation reduce systolic BP among individuals with prehypertension or stage 1 hypertension. The effect on BP reduction was not significantly different between soy protein and milk protein. To the best of our knowledge, this is the first randomized, controlled trial aimed at directly comparing the effect of vegetable protein (soy), dairy protein (milk), and carbohydrate on BP. These study findings may have important public health and clinical implications. It was estimated that a 2-mm Hg reduction in population systolic BP could lead to a 6% reduction in stroke mortality, 4% reduction in coronary heart disease mortality, and 3% reduction in all-cause mortality.4

The effect of soy protein on serum lipids has been well documented13; however, the effect of soy protein on BP has not been well studied. Washburn and colleagues14 compared the effect of 20 g of soy protein given either in 1 dose or in 2 doses with that of 20 g of complex carbohydrates on cardiovascular disease risk factors and menopausal symptoms among 51 women in a randomized, controlled trial. They observed a significant reduction in diastolic but not systolic BP in the twice-daily soy protein group only. Burke and colleagues9 reported that mean 24-hour ambulatory systolic and diastolic BP decreased significantly in those assigned to soy protein supplementation compared with control subjects on a low-protein diet among 41 treated hypertensive patients in a randomized, controlled trial. He and colleagues10 reported a significant reduction in systolic and diastolic BP among participants assigned to 40 g of soy protein per day compared with those assigned to carbohydrate control in a randomized, controlled trial of 302 Chinese participants with prehypertension or stage 1 hypertension. The present study provides further evidence that soy protein supplementation reduces BP and supports the notion that vegetable protein intake can be an important component of nutritional interventions for the prevention of hypertension.7

A diet that is rich in low-fat dairy products has been shown to reduce BP in clinical trials.15,16 The BP-lowering effect of dairy products has been hypothesized to be due to the high content of calcium and potassium in dairy products.17 To the best of our knowledge, this is the first clinical trial to document that milk protein lowers BP in prehypertension and stage 1 hypertension individuals. In the present study, calcium and potassium were matched among the soy protein, milk protein, and carbohydrate control groups. Therefore, the observed BP reduction in the present study was due to milk protein, not the calcium or potassium in these supplements. The OmniHeart randomized trial demonstrated that partial replacement of carbohydrate with protein (approximately half vegetable and half animal protein) reduced BP in adults with prehypertension or stage 1 hypertension.18 In addition, an 8-week randomized, parallel-design trial documented that

---

### Table 5. Mean (95% CI) Systolic and Diastolic BP According to Intervention Phase

<table>
<thead>
<tr>
<th></th>
<th>Soy Protein</th>
<th>Milk Protein</th>
<th>Carbohydrate</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systolic BP, mm Hg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beginning</td>
<td>126.1 (125.0–127.3)</td>
<td>125.9 (124.7–127.0)</td>
<td>125.2 (124.1–126.3)</td>
<td>0.26</td>
</tr>
<tr>
<td>Termination</td>
<td>124.6 (123.4–125.8)</td>
<td>124.3 (123.1–125.5)</td>
<td>125.9 (124.7–127.1)</td>
<td>0.002</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>-1.5 (-2.4 to -0.6)</td>
<td>-1.8 (-2.7 to -1.0)</td>
<td>0.5 (-0.4 to 1.3)</td>
<td>0.0007</td>
</tr>
<tr>
<td><strong>Diastolic BP, mm Hg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beginning</td>
<td>81.4 (80.7–82.2)</td>
<td>81.7 (80.9–82.4)</td>
<td>81.5 (80.8–82.2)</td>
<td>0.81</td>
</tr>
<tr>
<td>Termination</td>
<td>81.0 (80.3–81.8)</td>
<td>81.1 (80.3–81.9)</td>
<td>81.8 (81.0–82.5)</td>
<td>0.13</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>-0.2 (-0.9 to 0.5)</td>
<td>-0.5 (-1.2 to 0.2)</td>
<td>0.3 (-0.4 to 0.9)</td>
<td>0.27</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; BP, blood pressure.
modest substitution of carbohydrate intake with animal protein intake from lean red meat lowered BP in hypertensive persons.\textsuperscript{19}

There are inconsistent reports regarding whether vegetable or animal protein provides a better BP-lowering effect.\textsuperscript{6,8,20–25} Some observational epidemiological studies have identified an inverse association between dietary vegetable protein intake and BP.\textsuperscript{8,20–22} In contrast, other studies observed an inverse association between dietary animal protein intake and BP.\textsuperscript{23–25} Higher levels of dietary fiber, antioxidant vitamins, and potassium and lower levels of fat and sodium in vegetable protein–rich foods might confound the relationship between vegetable protein intake and BP.\textsuperscript{6} Likewise, higher levels of potassium, calcium, and magnesium in dairy products might confound the relationship between animal protein intake and BP. In the present randomized, controlled trial, with the exception of dietary protein and carbohydrate, other macronutrients and micronutrients were not changed during the 3-phase interventions with soy protein, milk protein, and carbohydrate supplementations. The present study indicates that both vegetable protein (soy) and dairy protein (milk) lower BP.

Isoflavones in soy protein have been reported to lower BP in clinical trials\textsuperscript{56}; however, this effect has been found to be inconsistent and not dose dependent. Dietary phosphorus is high in soy protein, and phosphorus has been inversely associated with BP in the INTERMAP study, a cross-sectional epidemiological study of 4680 adults 40 to 59 years of age from 4 countries.\textsuperscript{27} Milk protein is a rich source of angiotensin-I–converting enzyme inhibitory peptides. Animal experiments and human studies showed that these casokinin and lactokinins can reduce BP significantly.\textsuperscript{28} In addition, some amino acids might have direct BP-lowering effects.\textsuperscript{6} For example, a strong inverse association between dietary glutamic acid intake and BP has been observed in the INTERMAP study.\textsuperscript{29} Glutamic acid is a very common amino acid and constitutes 21.5\% of soy protein intake and 19.5\% of milk protein intake. Future studies should test the effects of individual amino acids on BP.

This randomized, controlled trial used a 3-phase crossover design, and BP measurements were carefully obtained during multiple visits at the baseline and termination of each phase. This design maximally minimized the influences of variations in lifestyle and diet among individual participants on BP changes during intervention. A prolonged washout period (3 weeks) and collection of baseline BP at each phase reduced the carryover effects of intervention. Limitations of this study include the relatively short duration of the intervention and the use of a high-glycemic-index refined carbohydrate supplement as control. Additional limitations include the lack of testing for a dose-response relationship between dietary protein intake and BP. Further studies should test the dose-response relationship between protein intake and BP.

Although a low-protein diet is widely used for patients with chronic kidney disease, its efficacy has been long debated.\textsuperscript{30} The Modification of Diet in Renal Disease Study randomized patients with chronic kidney disease to diets that contained different amounts of protein and did not find a significant difference in the mean decline in glomerular filtration rate.\textsuperscript{31} A meta-analysis of 13 randomized trials indicated that the effect of dietary protein restriction on retarding the rate of renal function decline was relatively weak and inconclusive.\textsuperscript{32}

In conclusion, the present study indicates that both soy and milk protein supplement reduce systolic BP compared with a high-glycemic-index refined carbohydrate supplement among patients with prehypertension and stage 1 hypertension. Previous studies have suggested that partial substitution of carbohydrate intake with protein intake lowers BP levels in patients with hypertension or prehypertension.\textsuperscript{18,19} Further randomized, controlled trials are required to examine the effect of various dietary proteins on BP in order to recommend an overall increase in dietary protein intake as part of a nutrition intervention strategy for the prevention and treatment of hypertension.

Acknowledgments
We acknowledge the exemplary contributions of the staff of the ProBP Study at Tulane University School of Public Health and Tropical Medicine (Deborah Bujnowska, Catherine Cooke, Linda Gaines, Lisa A. Harewood, Jorge Melara, Lora R. Nolen, Lindsey Powers, Kate Reed, Kathryn E. Royse, and Ji-Hua Xu) and at the University of Mississippi Medical Center (Cathy Adair, Bettie Davis, Olivia R. Henry, Maggie Ingram, Valerie McNair, Shannon M. Parkham, Susie Pepper, and Mary R. Pfeifer). Each named individual was compensated for his or her contribution as part of the grant support.

Sources of Funding
This work was supported by Award Number R01 HL68057 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Study supplements were provided for the ProBP study by Solae, LLC (St Louis, MO). Neither the National Heart, Lung, and Blood Institute nor Solae, LLC had any role in the design and conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.

Disclosures
None.

References
Observational epidemiological studies have reported an inverse association between dietary protein intake and blood pressure. We compared the effect of soy protein, milk protein, and complex carbohydrate supplementation on blood pressure in a randomized, double-blind crossover trial among 352 adults with prehypertension or stage 1 hypertension. The trial participants were assigned to take 40 g/d of soy protein, milk protein, or complex carbohydrate supplementation each for 8 weeks in a random order. A 3-week washout period was implemented between the interventions. Three blood pressure measurements were obtained at 2 baseline and 2 termination visits during each of the 3 intervention phases by use of a random-zero sphygmomanometer. Compared with carbohydrate controls, soy protein and milk protein supplementations were significantly associated with a -2.0 mm Hg (95% confidence interval -3.2 to -0.7 mm Hg, P=0.002) and -2.3 mm Hg (-3.7 to -1.0 mm Hg, P=0.0007) net change in systolic blood pressure, respectively. The results from this randomized, controlled trial indicate that both soy and milk protein intake reduce systolic blood pressure compared with carbohydrate intake among patients with prehypertension and stage 1 hypertension. Furthermore, these findings suggest that partially replacing carbohydrate with soy or milk protein might be an important component of nutrition intervention strategies for the prevention and treatment of hypertension.
Effect of Dietary Protein Supplementation on Blood Pressure: A Randomized, Controlled Trial
Jiang He, Marion R. Wofford, Kristi Reynolds, Jing Chen, Chung-Shiuan Chen, Leann Myers, Deborah L. Minor, Patricia J. Élmer, Daniel W. Jones and Paul K. Whelton

Circulation. published online July 18, 2011;
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2011/07/18/CIRCULATIONAHA.110.009159

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/